Biotechnology and Pharmaceutical Services Outsourcing Market study provides detailed information on market upcoming trends, new business development, drivers, capacities, and technologies. It covers ...
Sana is Incorporating the Tested Immune Evasion Technology to Develop SC451, a HIP-modified, Stem Cell-Derived Therapy as a One-Time Treatment for Patients with Type 1 Diabetes, with a Goal of Normal ...
First-in-Human Study Provides Evidence that Sana’s Hypoimmune (HIP) Technology Enables Transplanted Islet Cells to Avoid Immune Rejection and Produce Insulin Without Immunosuppression Results ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback